|会社名||Athersys Inc （アサ―シス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 アサーシス(Athersys Inc.)は主に再生医療の分野に焦点を当てた国際的なバイオ技術企業である。同社のマルチステム細胞療法（同種異系幹細胞製剤）は、リードプラットフォーム製品であり、後の段階の臨床開発段階にある。その臨床開発プログラムは、神経学的状態、心血管疾患、炎症性および免疫性障害、特定の肺疾患および多くの患者にとって注意の基準が限られているまたは不十分なその他の状態の治療に焦点を当てる。神経領域では、虚血性脳卒中による神経学的損傷の病歴を有する患者のマルチステム治療の可能性である第2相試験を評価した。同社は急性心筋梗塞（AMI）の病歴を有する患者に対するマルチステム細胞療法の投与のために米国で第II相臨床試験を開始した。 アサ―シスは、米国のバイオテクノロジ―企業。主に再生医療の分野に焦点を当て、炎症、免疫障害、神経学的疾患、心疾患、その他疾患の治療用の同種幹細胞製品を研究、開発、商品化する。主要なプラットフォ―ム製品は特許取得済の成人由来の量産可能な幹細胞製品MultiStem。本社はオハイオ州クリ―ブランド。 Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.|
|本社所在地||3201 Carnegie Avenue Cleveland OH 44115-2634 USA|
|代表者氏名||Gil Van Bokkelen ギルヴァンボケレン|
|代表者役職名||Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Athersys Inc. revenues increased from $2.1M to $20.5M. Net loss decreased 73% to $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other expense net increase from $84K to $295K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.11 to -$0.02.|
Surprising stocks: Instil Bio, Inc. (NASDAQ:TIL -2.22%), Athersys, Inc. (NASDAQ:ATHX -1.96%) 2023/02/27 10:46:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Surprising stocks: Instil Bio, Inc. (NASDAQ:TIL -2.22%), Athersys, Inc. (NASDAQ:ATHX -1.96%) appeared first on Stocks Equity .
Can you still get a good price for Athersys Inc. (ATHX) Shares at this point? 2023/02/15 14:32:00 US Post News
As of Tuesday, Athersys Inc.’s (NASDAQ:ATHX) stock closed at $1.49, down from $1.77 the previous day. While Athersys Inc. has underperformed by -16.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATHX fell by -93.55%, with highs and lows ranging from $33.25 to $0.50, whereas the […]
Enrapturing stocks: Tenax Therapeutics, Inc. (NASDAQ:TENX), Athersys, Inc. (NASDAQ:ATHX) 2023/02/15 12:46:27 Stock Equity
On 14-02-2023 (Tuesday) Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) encountered a difference of -16.51% after which it shut the day’ session at $0.91. The volume added 1,567,209 shares which compares … The post Enrapturing stocks: Tenax Therapeutics, Inc. (NASDAQ:TENX), Athersys, Inc. (NASDAQ:ATHX) appeared first on Stocks Equity .
ATHX stock gains on FDA nod to offer Phase 3 guidance for stroke candidate (NASDAQ:ATHX) 2023/02/14 14:26:39 Seeking Alpha
Athersys, Inc. (ATHX) added ~8% pre-market Tuesday after announcing that the FDA agreed to guide its Phase 3 development of MultiStem therapy for ischemic stroke. Read the full story here.
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion 2023/02/14 13:33:00 Athersys
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food Drug Administration (FDA). The Company was previously granted Regenerative Medicine Advanced Therapy (RMAT) and fast track designations for the use of MultiStem in the treatment of ischemic stroke. These designations enable sponsors to work closely with the FDA and receive its guidance on expediting advancement of designated programs. In the Type B meeting with the FDA, scheduled for late March, the Company intends to discuss proposed modifications to the ongoing pivotal Phase 3 MASTERS-2 clinical trial, which is under special protocol assessment (SPA) agreement. “This an important step forward as we continue to advance MASTERS-2,” commented Manal Morsy, M.D., Ph.D., MBA, Executive Vice President and Head of Global Regulatory Affairs.
Athersys to Participate in International Stroke Conference and BioProcess International 2023/01/30 16:20:00 Wallstreet:Online
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA. Any registered
ATHX, AVCT and TPST among mi-day movers 2023/01/11 17:44:07 Seeking Alpha
Gainers: Atlis Motor Vehicles (AMV) +220%.Broadwind BWEN +87%.Bed Bath & Beyond BBBY +42%.Forza (FRZA) +40%.Laser Photonics Corporation LASE +36%.Lipella Pharmaceuticals…
Athersys, Inc.: Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January 2023/01/11 17:12:00 Finanz Nachrichten
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today their participation in two January conferences, A…
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January 2023/01/11 17:11:00 Business Wire
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK. Ms. Maia Hansen, Chief Operating Officer, and Dr. Sarah Busch, Vice President of Regener
Alluring stocks: JanOne Inc. (NASDAQ:JAN), Athersys, Inc. (NASDAQ:ATHX) 2023/01/10 22:56:13 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Alluring stocks: JanOne Inc. (NASDAQ:JAN), Athersys, Inc. (NASDAQ:ATHX) appeared first on Stocks Equity .
Reasons To Keep this: Athersys, Inc. (NASDAQ:ATHX -10.16%), Neovasc Inc. (NASDAQ:NVCN -5.33%) 2022/09/15 00:11:53 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Reasons To Keep this: Athersys, Inc. (NASDAQ:ATHX -10.16%), Neovasc Inc. (NASDAQ:NVCN -5.33%) appeared first on Stocks Equity .
ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week 2022/09/12 15:37:45 InvestorPlace
We''re starting off another week with a deep dive into the short squeeze stocks traders are going to want to keep an eye on!
10 Short Squeeze Candidates That May Soar: Athersys, TDH Holdings, FaZe Holdings, Weber And More 2022/09/12 15:22:34 Benzinga
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Sept. 12, according to Fintel Data: Athersys: Biotechnology company Athersys Inc. (NASDAQ: ATHX ) jumped 13 positions to the top of the leaderboard from last week’s top short squeeze candidates. Data shows 102.1% of the float short and a cost to borrow of 18%. Shares traded for over $20 earlier this year before hitting new 52-week lows of $2.15 earlier this month. TDH Holdings: Pet food company TDH Holdings (NASDAQ: PETZ ) remains second on the short squeeze leaderboard for the second straight week . Data shows 27.2% of the float short, in line with the last two weeks. The cost to borrow on shares is 60%, up from last week’s reported 57.4%. Greenwich Lifesciences: Clinical stage biopharmaceutical company Greenwich Lifesciences Inc. (NASDAQ: GLSI ) rejoins the short squeeze leaderboard after several previous appearances , including the week of Aug. 22.
Watch this stock’s price performance: Athersys Inc. (NASDAQ:ATHX) 2022/09/07 16:16:00 US Post News
Athersys Inc. (ATHX)’s stock has witnessed a price hike of 4.48% from the previous close with its current price standing at $2.33. Its current price is -94.61% under its 52-week high of $43.19 and 6.39% more than its 52-week low of $2.19. Based on the past 30-day period, the stock price is -70.76% below the […]
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 アサ―シス ATHX Athersys Inc.）